JNJ
JNJ
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals

Johnson & Johnson

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks
$245.84
+3.35 (+1.38%)
As of Feb 24, 1:03 PM ET ·
Financial Highlights (FY 2026)
Revenue
93.28B
Net Income
26.54B
Gross Margin
67.9%
Profit Margin
28.5%
Rev Growth
+5.6%
D/E Ratio
0.59
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.9% 67.9% 44.0% 44.0%
Operating Margin 34.6% 31.1% 29.5% 29.2%
Profit Margin 28.5% 27.0% 19.9% 21.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 93.28B 88.33B 81.19B 89.13B
Gross Profit 63.32B 59.96B 35.72B 39.21B
Operating Income 32.26B 27.50B 23.92B 26.00B
Net Income 26.54B 22.62B 16.19B 19.43B
Gross Margin 67.9% 67.9% 44.0% 44.0%
Operating Margin 34.6% 31.1% 29.5% 29.2%
Profit Margin 28.5% 27.0% 19.9% 21.8%
Rev Growth +5.6% +5.6% +12.0% -8.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 109.95B 109.95B 181.05B 177.00B
Total Equity 187.05B 187.05B 426.62B 418.52B
D/E Ratio 0.59 0.59 0.42 0.42
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 39.61B 35.63B 32.24B 37.61B
Free Cash Flow — — 20.95B 18.85B